FDA to review effectiveness of Teva's Plan B in heavy women

A morning-after contraceptive pill sold in Europe may not work in women who weigh more than 176 pounds, regulators there said, triggering an FDA review of Teva Pharmaceutical's ($TEVA) PlanB One-Step product and its generic versions. Report (sub. req.)

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.